Daiwa SB Investments Ltd. Sells 1,670 Shares of Amgen, Inc. (AMGN)

Daiwa SB Investments Ltd. cut its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 23.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,450 shares of the medical research company’s stock after selling 1,670 shares during the period. Daiwa SB Investments Ltd.’s holdings in Amgen were worth $1,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the business. Telos Capital Management Inc. grew its stake in shares of Amgen by 7.7% during the first quarter. Telos Capital Management Inc. now owns 16,642 shares of the medical research company’s stock valued at $3,162,000 after buying an additional 1,187 shares during the last quarter. Huber Financial Advisors LLC grew its stake in shares of Amgen by 84.4% during the first quarter. Huber Financial Advisors LLC now owns 5,262 shares of the medical research company’s stock valued at $1,000,000 after buying an additional 2,409 shares during the last quarter. IFM Investors Pty Ltd grew its stake in shares of Amgen by 9.7% during the first quarter. IFM Investors Pty Ltd now owns 41,675 shares of the medical research company’s stock valued at $7,917,000 after buying an additional 3,697 shares during the last quarter. Carroll Financial Associates Inc. grew its stake in shares of Amgen by 2.8% during the first quarter. Carroll Financial Associates Inc. now owns 7,378 shares of the medical research company’s stock valued at $1,401,000 after buying an additional 201 shares during the last quarter. Finally, Stock Yards Bank & Trust Co. grew its stake in shares of Amgen by 7.2% during the first quarter. Stock Yards Bank & Trust Co. now owns 9,251 shares of the medical research company’s stock valued at $1,758,000 after buying an additional 625 shares during the last quarter. Institutional investors and hedge funds own 80.65% of the company’s stock.

In related news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total value of $386,360.00. Following the transaction, the director now owns 15,092 shares of the company’s stock, valued at $2,915,472.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 6,000 shares of company stock worth $1,115,580. 0.25% of the stock is owned by insiders.

A number of research firms have recently commented on AMGN. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Mizuho reaffirmed a “buy” rating and set a $208.00 target price on shares of Amgen in a research note on Friday, May 17th. Royal Bank of Canada set a $192.00 target price on Amgen and gave the company a “neutral” rating in a research note on Tuesday. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $190.00 target price on shares of Amgen in a research note on Wednesday, May 15th. Finally, Credit Suisse Group began coverage on Amgen in a research note on Monday. They set an “outperform” rating and a $208.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $209.30.

Shares of NASDAQ:AMGN opened at $169.69 on Wednesday. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $210.19. The company has a market capitalization of $102.71 billion, a P/E ratio of 11.78, a PEG ratio of 2.24 and a beta of 1.15. The company has a current ratio of 2.77, a quick ratio of 2.53 and a debt-to-equity ratio of 2.71.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The company had revenue of $5.56 billion for the quarter, compared to analysts’ expectations of $5.55 billion. During the same quarter in the prior year, the firm earned $3.47 earnings per share. Amgen’s revenue was up .1% compared to the same quarter last year. As a group, equities research analysts predict that Amgen, Inc. will post 13.94 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $1.45 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.42%. Amgen’s dividend payout ratio (DPR) is currently 40.28%.

ILLEGAL ACTIVITY NOTICE: “Daiwa SB Investments Ltd. Sells 1,670 Shares of Amgen, Inc. (AMGN)” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/22/daiwa-sb-investments-ltd-sells-1670-shares-of-amgen-inc-amgn.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: How Do Front-End Loads Impact an Investment?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.